The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $4.63, representing a -3.14% change from its previous ...
Recursion Pharmaceuticals Inc. stocks have been trading down by -4.08 percent after cautious reaction to its latest AI ...
ARK Invest sold $17.1M in Twist Bioscience shares and purchased Recursion Pharmaceuticals, Intellia Therapeutics, and ...
Cathie Wood’s ARK Invest continued to reshuffle its healthcare portfolio Monday across its ETFs, selling heavily in Twist Bioscience Corp TWST while directing fresh capital toward biotechnology and ...
Tempus AI slides 7.63% today to $77.22 as selling pressure emerges despite bullish momentum and FDA clearance news.
ARK Invest sold Twist Bioscience shares and bought Recursion Pharmaceuticals, Intellia Therapeutics, and Veracyte stock on ...
Pune, India, October 6th, 2026, FinanceWireThis is a paid advertisement.Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) ...
Across the ARK Genomic Revolution ETF and the ARK Innovation ETF, Wood bought $6.1 million in Recursion Pharmaceuticals, $1.2 million in Intellia Therapeutics, and $5.3 million in Veracyte.
Cathie Wood's ARK Invest executed a $22 million healthcare portfolio rotation on Monday, selling approximately $18 million of ...
- Recursion Pharmaceuticals RXRX+16.63% (RXRX) surges 16.38% on heavy volume, trading near $4.83 intraday high. - Extended 2029 Tempus AI TEM +8.11% partnership replaces $84M potential fees with $42M ...
Recursion’s August business update highlighted that Genentech opted its first neuroscience target into an early discovery ...
Recursion Pharmaceuticals Inc. stocks have been trading up by 15.41 percent amid heightened optimism over its AI-driven drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results